Drug
MK 2206 clinical trials
Also written MK2206.
- studies test it
- 44
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
- MK2206
- 44
Combined with it in one product
Studies by the year they started
43 studies that test it; most in 2011 (24)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 9 |
| 2011 | 24 |
| 2012 | 4 |
| 2013 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 30
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 39
National Cancer Institute (NCI) (30) · Merck Sharp & Dohme LLC (5) · Memorial Sloan Kettering Cancer Center (2) · M.D. Anderson Cancer Center (1) · Chinese University of Hong Kong (1) · University of California, San Francisco (1) · Centre Leon Berard (1) · National Taiwan University Hospital (1)
Often tested with
Tested in the same studies.
AZD 6244 (7) · Lapatinib (4) · Erlotinib (3) · Paclitaxel (2) · MK-0752 (2) · Trastuzumab (2) · Hydroxychloroquine (1) · Sunitinib (1)
Studies
Open first, then newest update. How each study uses MK 2206 is read from its arms, and is right about nine times in ten.
Testing it · 44
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01480154Written as Akt Inhibitor MK2206
- Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01251861Written as Akt Inhibitor MK2206
- Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedPhase 2National Cancer Institute (NCI)NCT01306045Written as MK-2206
- Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial CancerCompletedPhase 2National Cancer Institute (NCI)NCT01307631Written as Akt Inhibitor MK2206
- BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT01248247Written as MK-2206
- Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaCompletedPhase 2National Cancer Institute (NCI)NCT01258998Written as Akt inhibitor MK2206
- Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerTerminatedPhase 2National Cancer Institute (NCI)NCT01239342Written as Akt Inhibitor MK2206
- Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT01802320Written as Akt Inhibitor MK2206
- Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaCompletedPhase 2National Cancer Institute (NCI)NCT01604772Written as Akt Inhibitor MK2206
- Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT00670488Written as MK-2206
- Akt Inhibitor MK2206 in Treating Patients With Advanced Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT01277757Written as Akt Inhibitor MK2206
- AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT01253447Written as Akt inhibitor MK2206
- A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01243762Written as MK-2206
- A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)CompletedPhase 1Merck Sharp & Dohme LLCNCT01021748Written as MK-2206
- Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast CancerTerminatedPhase 2National Cancer Institute (NCI)NCT01776008Written as Akt Inhibitor MK2206
- Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedPhase 2National Cancer Institute (NCI)NCT01349933Written as Akt inhibitor MK2206
- Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedPhase 2National Cancer Institute (NCI)NCT01481129Written as Akt Inhibitor MK2206
- Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedPhase 1/2National Cancer Institute (NCI)NCT01369849Written as Akt Inhibitor MK2206
- MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast CancerTerminatedPhase 2National Cancer Institute (NCI)NCT01319539Written as Akt Inhibitor MK2206
- MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast CancerCompletedPhase 1National Cancer Institute (NCI)NCT01263145Written as Akt Inhibitor MK2206
See all 44 studies that test MK 2206 →
Given in every arm · 3 — MK 2206 is usual care beside what is tested
- A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)TerminatedPhase 1Merck Sharp & Dohme LLCNCT00963547Written as MK-2206
- A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)CompletedPhase 1Merck Sharp & Dohme LLCNCT00848718Written as MK-2206
- MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerCompletedPhase 1National Cancer Institute (NCI)NCT01344031Written as Akt Inhibitor MK2206
Codes
What other systems call MK 2206 · ClinicalTrials.gg INT005607
- UNII (FDA) 4HA45S22ZZMK-2206Confirmed FDA, Wikidata
- Wikidata Q104720539MK-2206 hydrochlorideConfirmed FDA, Wikidata
- NCI Thesaurus C225486MK-2206One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4HA45S22ZZ | MK-2206 | Confirmed FDA, Wikidata |
| Wikidata | Q104720539 | MK-2206 hydrochloride | Confirmed FDA, Wikidata |
| NCI Thesaurus | C225486 | MK-2206 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.